Trial · NCT03150056
Outcomes29
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 29 of 29
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Prostate-specific Antigen (PSA) Response Rate at Week 4 | Week 4 | Modified All Treated Population. | Percentage of participants | NUMBER |
| SECONDARY | Time to Disease Progression | Up to 21.3 months | Modified All Treated Population. | Days | MEDIAN |
| SECONDARY | Radiographic Progression-free Survival (rPFS) | Up to 21.3 montths | Modified All Treated Population. | Days | MEDIAN |
| SECONDARY | Number of Participants With Worst-Case Post Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status | Up to 21.3 months | All Treated Population. Only those participants with data available at the indicated time points were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Global Health Status (GHS) | Baseline (Week 1 Day 1, pre-dose) and on Day 1 of Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61 | Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles). | Scores on a scale | MEAN |
| SECONDARY | Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF): Pain Intensity- Pain at Worst in Last 24 Hours | Baseline (Pre-dose on Week 1 Day 1) and on Day 1 of Weeks 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61, 73, 85, 97 | Modified All Treated Population. Only those participants with data available at the indicated time points were analyzed (indicated by n=X in category titles). | Scores on a scale | MEAN |
| OTHER_PRE_SPECIFIED | Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) Until End of the Study | Up to 3 years and 11 months | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Number of Participants With AEs Leading to Any Dose Reduction or Delays Until End of the Study | Up to 3 years and 11 months | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Number of Participants Who Withdrew Due to Toxicity and Changes in Safety Assessment Until End of the Study | Up to 3 years and 11 months | All Treated Population | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03150056/outcomes?page=2